<p>理想情況下，您的整體投資組合應該超過市場平均水平。但幾乎每位投資者都肯定會擁有表現優異和表現不佳的股票。在這一點上，一些股東可能在質疑他們對 <strong>Tate &amp; Lyle plc</strong> (LON:TATE) 的投資，因為過去五年股價下跌了 53%。而一些最近的買家可能也感到擔憂，因為該股票在過去一年中下跌了 48%。股東們最近的表現更為糟糕，股價在過去 90 天內下跌了 29%。</p>
<p>由於股東們在長期內處於虧損狀態，讓我們看看這段時間的基本面，看看它們是否與回報一致。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>雖然市場是一個強大的定價機制，但股價反映的是投資者情緒，而不僅僅是基礎業務表現。評估公司情緒變化的一個有缺陷但合理的方法是將每股收益（EPS）與股價進行比較。</p>
<p>在股價下跌的五年中，Tate &amp; Lyle 的每股收益（EPS）每年下降了 28%。每股收益的下降幅度超過了 14% 的年複合股價下跌幅度。相對温和的股價反應可能是因為市場預計業務會有所好轉。以 47.44 的市盈率來看，可以説市場對該業務的未來持樂觀態度。</p>
<p>下圖顯示了每股收益隨時間的變化（如果您點擊圖像，可以看到更詳細的信息）。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/377904-earnings-per-share-growth-1-dark-2/1765614527926?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/377904-earnings-per-share-growth-1-dark-2/1765614527926"/></p>
<p>LSE:TATE 每股收益增長 2025 年 12 月 13 日</p>
<p>值得注意的是，我們在上個季度看到顯著的內部人士買入，這被我們視為積極信號。另一方面，我們認為收入和收益趨勢是衡量業務更有意義的指標。通過查看 Tate &amp; Lyle 的收益、收入和現金流的互動圖表，可以更深入地瞭解收益情況。</p>
<h2>股息情況如何？</h2>
<p>在考慮投資回報時，重要的是要考慮 <em>總股東回報</em> (TSR) 和 <em>股價回報</em> 之間的差異。TSR 是一種回報計算，考慮了現金股息的價值（假設收到的任何股息都被再投資）以及任何折扣資本籌集和分拆的計算價值。可以説，TSR 提供了股票產生的回報的更全面的圖景。在 Tate &amp; Lyle 的情況下，過去 5 年的 TSR 為-35%。這超過了我們之前提到的股價回報。因此，公司支付的股息提升了 <em>總</em> 股東回報。</p>
<h2>不同的視角</h2>
<p>Tate &amp; Lyle 的股東今年下跌了 46%（即使包括股息），但市場本身上漲了 20%。即使是優質股票的股價有時也會下跌，但我們希望在對業務產生濃厚興趣之前，看到基本指標的改善。不幸的是，去年的表現可能表明存在未解決的挑戰，因為其表現比過去五年年化損失 6% 還要糟糕。我們意識到巴倫·羅斯柴爾德曾説過，投資者應該在 “街頭有血時” 買入，但我們提醒投資者首先要確保他們購買的是高質量的企業。長期跟蹤股價表現總是很有趣。但要更好地理解 Tate &amp; Lyle，我們需要考慮許多其他因素。即便如此，請注意，Tate &amp; Lyle 在我們的投資分析中顯示出 <strong>4 個警告信號</strong>，其中 2 個令人擔憂……</p>
<p>Tate &amp; Lyle 並不是唯一一個內部人士在買入的股票。所以請查看這份 <strong>免費</strong> 的吸引人估值的小型公司名單，內部人士正在買入。</p>
<p><em>請注意，本文中引用的市場回報反映了目前在英國交易所交易的股票的市場加權平均回報。</em></p>
<p>移動基礎設施用於國防和災害</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

TATE

<p>Tate & Lyle (倫敦證券交易所代碼：TATE) 的股東在過去五年中面臨了 35% 的損失，期間股價下跌了 53%。公司的每股收益（EPS）年均下降 28%，這也是導致下滑的原因之一。儘管市盈率為 47.44，暗示市場樂觀，但總股東回報率（TSR）為-35%，表明分紅在一定程度上緩解了損失。近期內部人士的買入是一個積極信號，但公司面臨挑戰，投資分析中指出了 4 個警示信號</p>

<p>Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. At this point some shareholders may be questioning their investment in <strong>Tate &amp; Lyle plc</strong> (LON:TATE), since the last five years saw the share price fall 53%. And some of the more recent buyers are probably worried, too, with the stock falling 48% in the last year. Shareholders have had an even rougher run lately, with the share price down 29% in the last 90 days.</p>
<div class="lb-trans"><p>理想情況下，您的整體投資組合應該超過市場平均水平。但幾乎每位投資者都肯定會擁有表現優異和表現不佳的股票。在這一點上，一些股東可能在質疑他們對 <strong>Tate &amp; Lyle plc</strong> (LON:TATE) 的投資，因為過去五年股價下跌了 53%。而一些最近的買家可能也感到擔憂，因為該股票在過去一年中下跌了 48%。股東們最近的表現更為糟糕，股價在過去 90 天內下跌了 29%。</p>
</div><p>Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.</p>
<div class="lb-trans"><p>由於股東們在長期內處於虧損狀態，讓我們看看這段時間的基本面，看看它們是否與回報一致。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.</p>
<div class="lb-trans"><p>雖然市場是一個強大的定價機制，但股價反映的是投資者情緒，而不僅僅是基礎業務表現。評估公司情緒變化的一個有缺陷但合理的方法是將每股收益（EPS）與股價進行比較。</p>
</div><p>During the five years over which the share price declined, Tate &amp; Lyle's earnings per share (EPS) dropped by 28% each year. This fall in the EPS is worse than the 14% compound annual share price fall. The relatively muted share price reaction might be because the market expects the business to turn around. With a P/E ratio of 47.44, it's fair to say the market sees a brighter future for the business.</p>
<div class="lb-trans"><p>在股價下跌的五年中，Tate &amp; Lyle 的每股收益（EPS）每年下降了 28%。每股收益的下降幅度超過了 14% 的年複合股價下跌幅度。相對温和的股價反應可能是因為市場預計業務會有所好轉。以 47.44 的市盈率來看，可以説市場對該業務的未來持樂觀態度。</p>
</div><p>The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).</p>
<div class="lb-trans"><p>下圖顯示了每股收益隨時間的變化（如果您點擊圖像，可以看到更詳細的信息）。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/377904-earnings-per-share-growth-1-dark-2/1765614527926" alt="" original-src="https://images.simplywall.st/asset/chart/377904-earnings-per-share-growth-1-dark-2/1765614527926"/></p>
<p>LSE:TATE Earnings Per Share Growth December 13th 2025</p>
<div class="lb-trans"><p>LSE:TATE 每股收益增長 2025 年 12 月 13 日</p>
</div><p>It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. Dive deeper into the earnings by checking this interactive graph of Tate &amp; Lyle's earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>值得注意的是，我們在上個季度看到顯著的內部人士買入，這被我們視為積極信號。另一方面，我們認為收入和收益趨勢是衡量業務更有意義的指標。通過查看 Tate &amp; Lyle 的收益、收入和現金流的互動圖表，可以更深入地瞭解收益情況。</p>
</div><h2>What About Dividends?</h2>
<div class="lb-trans"><h2>股息情況如何？</h2>
</div><p>When looking at investment returns, it is important to consider the difference between <em>total shareholder return</em> (TSR) and <em>share price return</em>. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Tate &amp; Lyle, it has a TSR of -35% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the <em>total</em> shareholder return.</p>
<div class="lb-trans"><p>在考慮投資回報時，重要的是要考慮 <em>總股東回報</em> (TSR) 和 <em>股價回報</em> 之間的差異。TSR 是一種回報計算，考慮了現金股息的價值（假設收到的任何股息都被再投資）以及任何折扣資本籌集和分拆的計算價值。可以説，TSR 提供了股票產生的回報的更全面的圖景。在 Tate &amp; Lyle 的情況下，過去 5 年的 TSR 為-35%。這超過了我們之前提到的股價回報。因此，公司支付的股息提升了 <em>總</em> 股東回報。</p>
</div><h2>A Different Perspective</h2>
<div class="lb-trans"><h2>不同的視角</h2>
</div><p>Tate &amp; Lyle shareholders are down 46% for the year (even including dividends), but the market itself is up 20%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. We realise that Baron Rothschild has said investors should &#34;buy when there is blood on the streets&#34;, but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Tate &amp; Lyle better, we need to consider many other factors. Even so, be aware that Tate &amp; Lyle is showing <strong>4 warning signs in our investment analysis</strong> , and 2 of those are concerning...</p>
<div class="lb-trans"><p>Tate &amp; Lyle 的股東今年下跌了 46%（即使包括股息），但市場本身上漲了 20%。即使是優質股票的股價有時也會下跌，但我們希望在對業務產生濃厚興趣之前，看到基本指標的改善。不幸的是，去年的表現可能表明存在未解決的挑戰，因為其表現比過去五年年化損失 6% 還要糟糕。我們意識到巴倫·羅斯柴爾德曾説過，投資者應該在 “街頭有血時” 買入，但我們提醒投資者首先要確保他們購買的是高質量的企業。長期跟蹤股價表現總是很有趣。但要更好地理解 Tate &amp; Lyle，我們需要考慮許多其他因素。即便如此，請注意，Tate &amp; Lyle 在我們的投資分析中顯示出 <strong>4 個警告信號</strong>，其中 2 個令人擔憂……</p>
</div><p>Tate &amp; Lyle is not the only stock insiders are buying. So take a peek at this <strong>free</strong> list of small cap companies at attractive valuations which insiders have been buying.</p>
<div class="lb-trans"><p>Tate &amp; Lyle 並不是唯一一個內部人士在買入的股票。所以請查看這份 <strong>免費</strong> 的吸引人估值的小型公司名單，內部人士正在買入。</p>
</div><p><em>Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges.</em></p>
<div class="lb-trans"><p><em>請注意，本文中引用的市場回報反映了目前在英國交易所交易的股票的市場加權平均回報。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災害</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達，隨處可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

Tate & Lyle (LON:TATE) 的股東在五年前投資該股票後，已經遭受了 35% 的損失